Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches

The extracted text does not present a formal methods section or a prespecified search strategy, so this paper should be interpreted as a narrative review rather than a systematic review or meta-analysis with reproducible search and selection criteria. The authors summarise and synthesise multiple sources of evidence, including randomized controlled trials, crossover trials, open‑label reports, meta-analyses, observational studies, and mechanistic research. Where available, the review reports results and key numerical findings from major trials (for example, the International Suicide Prevention Trial for clozapine) and from ketamine clinical trials (open-label, crossover, and randomized trials). Tables are referenced in the text as summarising studies, but the extracted text does not reproduce a search strategy, inclusion/exclusion criteria, study selection flow, or a formal risk-of-bias assessment. Consequently, details on how studies were identified, selected, or pooled are not clearly reported in the extracted material.

Somatic treatments with evidence for suicide-risk reduction are described in several classes. Clozapine was approved by the FDA for reducing recurrent suicidal behaviour in schizophrenia/schizoaffective disorder on the basis of a large trial of 956 high‑risk patients randomised to clozapine (200–900 mg/day) or olanzapine (5–20 mg/day). Over 2 years, clozapine-treated patients had significantly fewer suicide attempts (34 vs 55; P=0.03), fewer suicide-attempt hospitalizations (82 vs 107; P=0.05), fewer rescue interventions (118 vs 155; P=0.01), and reduced concomitant antidepressant and anxiolytic use. A meta-analysis cited reported nearly a threefold lower relative risk for completed suicide with clozapine compared with other treatments. Lithium is effective in mood disorders for preventing relapse and as augmentation in treatment-resistant depression. Practice guidelines cited in the review recommend considering lithium to reduce suicide risk in depressive disorders. Observational studies and meta-analyses reported substantial reductions in suicide; for instance, Cipriani and colleagues found that among patients with unipolar depression lithium reduced the risk of death by suicide (OR=0.13, 95% CI 0.02–0.76) and all-cause mortality (OR=0.36, 95% CI 0.13–0.98), and lithium decreased suicide risk approximately 4–5-fold compared with placebo in pooled analyses. The antidepressant literature is mixed but includes large meta-analyses suggesting overall protective effects against suicide when compared with placebo. One large meta-analysis of hundreds of trials reported reduced suicide risk among treated patients; SSRIs in particular have been associated with reduced suicidal behaviour in some pooled analyses. However, the 2004 FDA warning about increased suicide risk in children and adolescents on antidepressants is discussed; the review notes that this risk may relate to treatment-emergent agitation, insomnia, akathisia, or activation in unrecognised bipolarity, while the same FDA data also indicated an overall protective effect against new or worsening suicidal ideation. Practice guidelines continue to support antidepressant use across age groups when indicated for depression. Electroconvulsive therapy (ECT) remains a rapid and effective somatic option for suicidal depression. Data from the Consortium for Research in ECT identified 131 patients at high acute suicide risk (HRSD‑24 suicide item scores of 3–4) and documented progressive resolution of suicidal ideation during an ECT course, with the cumulative percentages of patients scoring zero on the HRSD‑24 suicide item after 1, 3, 6, and 9 ECT sessions being 15.3%, 38.2%, 61.1%, and 76.3%, respectively. The authors note, however, that maintenance of suicide-risk reduction after stopping ECT is not well documented. Ketamine pharmacology and clinical efficacy are reviewed in detail. Ketamine is an NMDA receptor antagonist with a complex receptor profile and an elimination half‑life of approximately 2–2.5 hours; it is metabolised via CYP2B6, CYP3A4, and to a lesser extent CYP2C9 into norketamine and dehydronorketamine. Clinical formulations include racemic IV preparations and (S)-ketamine; the S-enantiomer has higher NMDA receptor affinity and may have a distinct tolerability profile. Numerous administration routes are available (IV, IM, intranasal, sublingual, oral, etc.), which is noted as a practical advantage. Early clinical reports documented rapid antidepressant effects in treatment-resistant depression (TRD): Berman et al. reported that 4 of 8 patients achieved ≥50% HRSD‑24 reduction at 72 hours after infusion, and Zarate et al. (crossover) found response rates of 71% at 24 h, 47% at 72 h, 35% at 1 week, and 12% at 2 weeks among 17 subjects. A larger parallel‑arm, triple-masked RCT by the authors’ group randomised 72 TRD patients to ketamine (0.5 mg/kg over 40 minutes) or midazolam; ketamine produced a 7.95‑point greater improvement in MADRS at 24 hours (95% CI 3.20–12.71), corresponding to a large effect size (Cohen’s d=0.81), and increased likelihood of response at 24 h (OR=2.18, 95% CI 1.21–4.14, P<0.006). Evidence specifically addressing suicidal ideation and behaviour shows rapid reductions in suicidal measures following ketamine infusion across multiple study designs. DiazGranados et al. reported rapid SSI and HRSD suicide-item improvement after a single open‑label ketamine infusion in 33 TRD patients, with effects apparent at the end of the 40‑minute infusion and persisting to 230 min but returning to baseline by 24–48 h. A double-blind crossover study in 15 bipolar depression patients found significant drug-by-time interactions for suicide items on the MADRS, HDRS and BDI, with reductions from 40 min up to 3 days post-infusion. Price and colleagues reported a mean decrease of 2.08 points on the MADRS suicide item at 24 h among 26 TRD patients (d=1.37). In a repeated-infusion subset (six infusions over 2 weeks), substantial and sustained reductions in the MADRS suicide item were reported (for example, a 2.8‑point decrease after the first infusion and similar decreases after the sixth). Al Jurdi and colleagues’ triple‑blind RCT of 57 TRD patients randomised 2:1 to ketamine versus midazolam found that 24 hours post-infusion 53% of ketamine-treated patients scored zero on three combined suicide measures versus 24% on midazolam (χ2=4.6; P=0.03). Larkin and Beautrais reported rapid decreases in MADRS suicide-item scores after a 0.2 mg/kg IV bolus in 14 emergency-room patients presenting with suicidal ideation, with reductions sustained at 7 days in the reported sample. Mechanistic literature discussed includes serotonergic dysfunction, hypothalamic–pituitary–adrenal (HPA) axis abnormalities (for example, abnormal dexamethasone suppression tests associated with higher future suicide risk), and immune‑inflammatory markers. The review highlights the kynurenine pathway: tryptophan is largely metabolised to kynurenine, which can be further converted to quinolinic acid (QUIN, an NMDA agonist) or kynurenic acid (KYNA, an endogenous NMDA antagonist). Inflammatory states and dysregulated glucocorticoids favour the QUIN arm and reduced serotonin synthesis. Ketamine may counteract QUIN-mediated NMDA activation and has been associated with reduced circulating proinflammatory cytokines (TNF‑α, IL‑8, IL‑6, IL‑1β) in settings with inflammatory stimuli, leading the authors to hypothesise that ketamine’s anti‑suicidal effect involves interruption of a self‑inducing kynurenine/inflammatory cascade, modulation of a hyperglutamatergic state, and restoration of serotonin homoeostasis.

The authors emphasise the complexity of suicide as a multifactorial phenomenon involving interacting genetic, environmental and biological systems, and they note important constraints on the literature. Animal models are of limited applicability because suicidal behaviour is not readily modelled, and suicide cuts across diagnostic categories which may obscure specific mechanisms. Because of the low base rate of completed suicide and the heterogeneity of contributing mechanisms, the investigators argue that much larger samples and standardised longitudinal measures are required to clarify treatment effects. Biases affecting interpretation of treatment effects on suicidal behaviour are discussed in depth. Randomized trials often exclude actively suicidal patients and those with comorbidities that increase suicide risk, limiting generalisability and potentially underpowering trials to detect differences in suicidal outcomes. The authors note that ethical and methodological designs can nevertheless address suicidal patients safely—for example by using surrogate outcomes, judicious rescue medications, and enhanced psychosocial monitoring. They also describe bias in longer‑term observational comparisons: discontinuation studies may be confounded because predictors of nonresponse (and hence discontinuation) overlap with suicide risk. The review cites a study showing that even patients who did not benefit from lithium’s relapse-prevention effects had lower suicidal behaviour, illustrating complexity in causal interpretation. Given these limitations, the authors counsel caution in interpreting the ketamine literature despite consistent signals of rapid reductions in suicidal ideation. They state that no published randomised controlled trials have been conducted specifically in the highest‑severity or highest‑risk suicidal groups. A search of ClinicalTrials.gov (June 2014) identified 85 open interventional suicide studies, of which 17 list suicide or suicidal behaviour reduction as an outcome; ketamine was the investigational drug in seven studies (one open‑label and multiple double‑blind RCTs, including comparisons versus midazolam), and one placebo‑controlled study was testing an NR2B subunit antagonist. Overall, the authors conclude that while ketamine shows promise because of its prompt actions in some patients, the available data are not yet sufficient to justify routine clinical integration without larger, replicated randomised studies that explicitly address suicidal populations.

The review concludes that evidence on the neurobiology and pharmacotherapy of suicide remains limited. Clozapine and lithium have the strongest pharmacological evidence for reducing suicide risk in specific populations, and ketamine represents a promising additional treatment because of rapid effects on depressive symptoms and suicidal ideation in multiple small studies. However, no published randomized controlled trials have specifically assessed ketamine’s efficacy in the highest‑severity suicidal groups, and current data are insufficient to support routine clinical implementation. Ongoing clinical trials, including several testing ketamine, were noted as necessary to determine ketamine’s role in suicide prevention.